[China BD 2025] Sciwind Biosciences and Verdiva Bio enters 2.47 Billion USD License on Three Metabolic Diseases Product Candidates

Announced Date: 2025-01-10 ( January 10, 2025)

Licensor (Seller): Sciwind Biosciences (China)

Licensee (Buyer):  Verdiva Bio (US)

.

Assets:

. Ecnoglutide Oral (XW004, VRB-101)

A phase 2-ready, once-weekly oral GLP-1 receptor agonist

. Oral Amylin Receptor Agonist (Amylin RA), VRB-103

A once-weekly, oral amylin receptor agonist in IND-enabling studies

. Subcutaneous injectable Amylin Receptor Agonist (Amylin RA), VRB-102

A long-acting, amylin receptor agonist in IND-enabling studies

.

Scope of Authority:

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea.

Sciwind has retained the rights to develop, manufacture and commercialize these products in all other regions.

.

Payment Detail:

Sciwind receives an upfront consideration totaling approximately USD 70 million, and is eligible to receive more than USD 2.4 billion in milestone payments for development, regulatory approvals and commercialization of above-mentioned partnered programs.

.

Additionally, Sciwind is also eligible to receive tiered royalties on future product sales outside of greater China and South Korea.

Furthermore, the two companies will collaborate on additional preclinical stage programs, and Sciwind is eligible to receive milestones and royalty payments based on the advancement of those programs.

.

Link:

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio (prnewswire.com)

.

Note:

Chinese Name of Sciwind Biosciences 先为达生物